The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation

Journal of Neuro-Oncology

Volumn 30, Issue 1, 1996, Pages 1-6

  Lamond, John P ^a   Mehta, Minesh P ^a   Boothman, David A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Glioma; Radiosensitizers; Topoisomerase I; Topotecan

Indexed keywords

9 AMINOCAMPTOTHECIN; DNA TOPOISOMERASE; ENZYME INHIBITOR; IRINOTECAN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; RADIOSENSITIZATION;

EID: 0029814282     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00177437     Document Type: Article

References (52)

1. Fleischmann G, Pflugfelder G, Steiner EK, Javaherian K, Howard GC, Wang JC, Elgin SCR: Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc Natl Acad Sci USA 81:6958-6962,1984
2. Wang JC: DNA topoisomerases. Ann Rev Biochem 54:665-697, 1985
3. Li LH, Fraser TJ, Olin EJ: Action of Camptothecin on mammalian cells in culture. Cancer Res 32: 2643-2650, 1972
4. Wall ME, Wani MC, Cook CE, Plumer KH, McPhail AT, Sim GA: Plant antitumor agents. I. The isolation and structure of Camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Campotheca acuminata. J Amer Chem Soc 88: 3888-3890, 1966
5. Gottlieb JA, Luce JK: Treatment of malignant melanoma with Camptothecin (NSC-100880 -. Cancer Chemother Rep 56: 03-105, 1972
6. Gottlieb JA, Guarino AM, Call JB: Preliminary pharmacologic and clinical evaluation of Camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461-470, 1970
7. Moertel CG, Schut AJ, Reitemeier RJ: Phase II study of Camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972
8. Muggia FM, Creaven PJ, Hansen H: Phase I clinical trial of weekly and daily treatment with Camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972
9. Eng W, Facette L, Johnson RK, Sternglanz R: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of Camptothecin. Mol Pharmacol 34: 755-760, 1988
10. Hsaing Y-H, Liu LF: Identification of mammary DNA topoisomerase I as an intra cellular target of the anti cancer drug Camptothecin. Cancer Res 48:1722-1726, 1988
11. Madden KR, Champoux JJ: Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to Camptothecin. Cancer Res 52:525-532, 1992
12. Mattern MR, Mong S-M, Bartus HF, Mirabelli CK, Crooke ST, Johnson RK: Relationship between the intracellular effects of Camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 47: 1793-1798, 1987
13. Giovanella BC, Stehlin JS, Wall ME: DNA topoisoraerase I-targeted chemotherapy of human colon cancer in xeno-grafts. Science 246:1046-1048, 1989
14. Kingsbury WD, Boehm JC, Jakas DR: Synthesis of water soluble (aminoalkyl) Camptothecin analogues: inhibition of topoisomerase I and anti-tumor activity. J Med Chem 34: 98-107, 1991
15. Kunimoto T, Nitta K, Tanaka T: Antitumor activity of 7-ethyl-10-[4-(piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of Camptothecin, against murine tumors. Cancer Res 47: 5944-5947, 1987
16. Matsuzaki T, Tokokura T, Mutai M: Inhibition of spontaneous and experimental metastasis by a new derivative of Camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21: 308-312, 1988
17. Burris HA III, Hanouske A-R, Johnson RK: Activity of Topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84: 1816-1820, 1992
18. Rowinski EK, Sartorius S, Grochow L: Phase I and pharmacological study of Topotecan. A novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656, 1992
19. Verweij J, Lund B, Beynen J: Clinical studies with Topotecan: The EORTC Experience (Abstract). Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, p 118, 1992
20. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerasel inhibition by Camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28: 4629-4638, 1989
21. Hsiang Y-H, hertzberg R, Hecht S, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
22. Avemann K, Knippers R, Koller T: Campothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol Cell Biol 8: 3026-3034, 1988
23. Del Bino G, Lassota P, Darzynkiewicz Z: The S-phase cyto-toxicity of Camptothecin. Exp Cell Res 193: 27-35, 1991
24. Hsaing Y-H, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by Camptothecin. Cancer Res 49: 5077-5082, 1989
25. Porter SE, Champoux JJ: The basis for Camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucl Acids Res 17: 8521-8532, 1989
26. Ryan AJ, Squires S, Strutt HL, Johnson RT: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucl Acids Res 19: 3295-3300, 1991
27. Zhang H, D'Arpa P, Liu LF: A model for tumor cell killing by topoisomerase poissons. Cancer Cells (Cold Spring Harbor) 2: 23-27, 1990
28. Friedman HS, Houghton PJ, Schold SC: Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin (Topotecan) against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34:171-174, 1994
29. Blaney SM, Cole DE, Balis FM: Plasma and cerebrospinal fluid pharmacokinetic study of Topotecan in nonhuman primates. Cancer Res 53: 725-727, 1993
30. Pratt CB, Stewart C, Santana VM: Phase I study of Topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12: 539-543, 1994
31. Eisenhauer EA, Wainman N, Boos G: Phase II trials of Topotecan in patients with malignant glioma and soft tissue sarcoma (Abstract). Proc Am Soc Clin Oncol 13:175, 1994
32. Boothman DA, Pardee AB: Inhibition of radiation-induced neoplastic transformation by β-lapachone. Proc Natl Acad Sci USA 86: 4963-4967, 1989
33. Boothman DA, Greeg S, Pardee AB: Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res 47: 5361-5367, 1987
34. Boothman DA, Schlegel R, Pardee AB: Anticarcinogenic potential of DNA repair inhibitors. Mutat Res 202:393-411, 1989
35. Boothman DA, Wang M, Schea R, Burrows HL, Strickfaden S, Owens KJ: Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int J Radiat Oncol Biol Phys 24: 939-948, 1992
36. Boothman DA: Enhanced malignant transformation is accompanied by increased survival recovery after ionizing radiation in Chinese hamster embryo fibroblasts. Rad Res 138: 5121-5125, 1994
37. Boothman DA, Trask DK, Pardee AB: Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res 49: 605-612, 1989
38. Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA: Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum (II)-sensitive and -resistant cells in vitro and in the FS all C fibrosarcoma in vivo. Int J Cancer 53: 118-123, 1993
39. Del Bino G, Bruno S, Yi PN, Darzynkiewicz Z: Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif 25: 537-548, 1992
40. Falk SJ, Smith PJ: DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int J Radiat Biol 61: 749-757, 1992
41. Hennequin C, Giocanti N, Balosso J, Favaudon V: Interaction of ionizing radiation with the topoisomerase I poison Camptothecin in growing V-79 and HeLa cells. Cancer Res 54: 1720-1728, 1994
42. Kim JH, Kim SH, Kolozsvary A, Khil MS: Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by Topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 22:515-518, 1992
43. Mattern MR, Hoffman GA, McCabe FL, Johnson RK: Synergistic cell killing by ionizing radiation and the topoisomerase I inhibitor, Topotecan (SK&F 104864). Cancer Res 57: 5813-5816, 1991
44. Musk SR, Steele GG: The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. B r J Cancer 62: 364-367, 1990
45. Roffler SK, Chan V, Yeh MY: Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res 54: 1276-1285, 1994
46. Lamond JP, Wang M, Kinsella TJ, Boothman DA: Radiation lethality enhancement with 9-Aminocamptothecin: comparison to other topoisomerase I inhibitors. Int J Radiat Oncol Biol Phys (in press)
47. Lamond JP, Wang M, Kinsella TJ, Boothman DA: Concentration and timing dependence of lethality enhancement between Topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int J Radiat Oncol Biol Phys (in press)
48. Boothman DA, Fukunaga N, Wang M: Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res 54: 4618-4626, 1994
49. Hirabayashi N, Kim R, Nishiyama M: Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues (Abstract). Proc Am Assoc Cancer Res 33: 436, 1992
50. Husain I, Mohler JL, Seigler HF, Besterman JM: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54: 539-546, 1994
51. Van Der Zee AG, Hollema H, DeJong S: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915-5920, 1991
52. Schiller JH, Kim K, Johnson D: Phase II study of Topotecan in extensive stage small cell lung cancer (Abstract). Proc ASCO 13: 330, 1994